Neuroendocrine Tumors Market: Epidemiology, Therapies, Companies, DelveInsight | ITM Solucin GmbH, Camurus, Ipsen, Takeda, Exelixi, BMS, RayzeBio, Radiomedix, OranoMed, Crinetics Pharmaceuticals, Chimerix, Perspective Therapeutics, Teclison, Chimeric Ther

Neuroendocrine Tumors therapies, such as CAM2029, CABOMETYX (cabozantinib), RYZ101 (actinium-225 DOTATATE), AlphaMedix, Paltusotine, ONC201, VMT-α-NET, Tirapazamine, CHM-2101, and others, are expected to boost the Neuroendocrine Tumors Market in the upcoming years.

DelveInsight has launched a new report on "Neuroendocrine Tumors - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Neuroendocrine Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Neuroendocrine Tumors market report @ https://www.delveinsight.com/report-store/neuroendocrine-tumors-net-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Neuroendocrine Tumors Market Report:

In 2023, the U.S. market for neuroendocrine tumors (NETs) was valued at approximately USD 1.53 billion and is projected to expand at a notable compound annual growth rate (CAGR) over the coming years.
The pharmaceutical industry has increasingly focused on radioactive isotopes in recent years, recognizing their growing utility in both the diagnosis and treatment of various cancers.
Treatment strategies for NETs are evolving, with a growing preference for endoscopic methods that can often eliminate the need for surgical intervention. Many NETs are now being discovered during routine procedures like colonoscopies and endoscopies, and smaller tumors are frequently removed on the spot.
Long-acting somatostatin analogs, particularly Novartis' **SANDOSTATIN LAR**, have long been a standard first-line treatment for NETs. While the drug initially experienced strong commercial success, its sales have recently declined in Europe due to the emergence of generic alternatives. However, no generic version has been approved in the U.S. yet, mainly due to the complexity of its formulation. Teva Pharmaceuticals attempted to develop a generic version but did not succeed, leaving an opportunity for other competitors to enter the market.
Currently, only beta-emitting radioisotopes are approved for use, but the industry is increasingly turning its attention toward alpha emitters. These particles deliver higher linear energy transfer (LET), making them more effective at inflicting cellular damage and potentially overcoming resistance to existing therapies. Companies like **Bristol Myers Squibb (BMS)/RayzeBio, Radiomedix/Orano Med, and Perspective Therapeutics** are actively pursuing developments in this area.
On March 5, 2025, the FDA approved Cabometyx for the treatment of adults and pediatric patients aged 12 and older with previously treated, locally advanced or metastatic, well- or moderately differentiated pancreatic neuroendocrine tumors (pNETs) and extra-pancreatic NETs (epNETs). This approval provides a new treatment option for patients with these rare and challenging cancers.
In April 2024, the FDA approved Lutathera for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This marks the first FDA approval of a therapy specifically for this patient group. The approval was based on a trial demonstrating a safety profile consistent with that observed in adults, leading to its initial approval for adult patients.
The NETs treatment landscape is supported by a robust pipeline, with numerous companies advancing new therapies. Notable players in the field include **ITM Solucin GmbH, Camurus, Ipsen, Takeda, Exelixis, BMS, RayzeBio, Radiomedix, Orano Med, Crinetics Pharmaceuticals, Chimerix, Perspective Therapeutics, Teclison, Chimeric Therapeutics, PharmaMar, Incyte Corporation, Enterome, and Elicera Therapeutics**, among others.
Promising Neuroendocrine Tumors therapies include CAM2029, CABOMETYX (cabozantinib), RYZ101 (actinium-225 DOTATATE), AlphaMedix, Paltusotine, ONC201, VMT-α-NET, Tirapazamine, CHM-2101, and others.

Neuroendocrine Tumors Overview

Neuroendocrine Tumors (NETs) can originate in various parts of the body. Like other cancers, NETs are named based on their site of origin-for example, a NET that develops in the lungs is referred to as a lung NET. This is considered the primary tumor. If the cancer spreads to other areas of the body, it becomes known as secondary or metastatic cancer. Most NETs arise from the gastrointestinal tract, including the stomach, small intestine, colon, pancreas. Comparatively fewer NETs originate in the lungs.

NETs may also begin in other areas such as the esophagus, appendix, skin, prostate, uterus, adrenal glands, and other organs. These tumors are categorized in different ways: they can be functional (producing hormones) or non-functional, and may behave in an indolent (slow-growing) or aggressive manner. The World Health Organization (WHO) has developed its own classification system for NETs. While the precise cause of NETs remains unclear, several risk factors have been identified, such as pituitary adenomas, Von Hippel-Lindau (VHL) syndrome, and pheochromocytomas. NETs can vary in growth rate, and many grow very slowly-some may remain stable for months or even years, meaning immediate treatment may not be necessary.

Neuroendocrine Tumors Market Outlook

For many individuals diagnosed with neuroendocrine tumors (NETs), somatostatin analogs (SSAs) are considered the standard first-line treatment. These drugs not only help manage symptoms through their hormone-suppressing (antisecretory) effects but are also believed to have tumor growth-inhibiting (antiproliferative) properties. Multiple studies have shown that patients treated with SSAs tend to experience longer periods before tumor progression and improved overall survival compared to those given a placebo.

In addition to SSAs, newer treatment strategies have emerged. One such option is the targeted therapy everolimus, an mTOR inhibitor. However, cytotoxic chemotherapy is generally ineffective in treating gastrointestinal NETs (GI-NETs). Recently, peptide receptor radionuclide therapy (PRRT) has been introduced as a novel treatment for patients whose NETs have not responded to conventional therapies. Nonetheless, outcomes for those with metastatic NETs remain unfavorable despite these advances.

According to guidelines from the National Comprehensive Cancer Network (NCCN) and ENETS, SSAs are recommended as the initial treatment when somatostatin receptor (SSTR)-based imaging is positive, the tumor is slow-growing, and the tumor grade is low. If the tumor is more aggressive, grows quickly, or does not show strong SSTR expression on imaging, everolimus may be used as a first-line alternative. Otherwise, everolimus is typically reserved for second-line therapy.

For lung NETs that continue to progress despite treatment with SSAs and everolimus, other treatment options include chemotherapy (using various protocols), PRRT, nonsurgical locoregional therapies, or participation in clinical trials exploring experimental treatments.

Discover how the Neuroendocrine Tumors market is rising in the coming years @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-net-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Neuroendocrine Tumors Marketed Drugs:

LUTATHERA (lutetium Lu 177 dotatate): Advanced Accelerator Applications (AAA)/Novartis
SOMATULINE DEPOT (lanreotide): Ipsen Biopharmaceuticals

Neuroendocrine Tumors Emerging Drugs:
ITM-11 (n.c.a. 177Lu-edotreotide): ITM Solucin GmbH
CAM2029: Camurus

Scope of the Neuroendocrine Tumors Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Neuroendocrine Tumors Companies: ITM Solucin GmbH, Camurus, Ipsen, Takeda, Exelixi, BMS, RayzeBio, Radiomedix, OranoMed, Crinetics Pharmaceuticals, Chimerix, Perspective Therapeutics, Teclison, Chimeric Therapeutics, PharmaMar, Incyte Corporation, Enterome, Elicera Therapeutics, and others
Neuroendocrine Tumors Therapeutic Assessment: Neuroendocrine Tumors current marketed and Neuroendocrine Tumors emerging therapies
Neuroendocrine Tumors Market Dynamics: Neuroendocrine Tumors market drivers and Neuroendocrine Tumors market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Neuroendocrine Tumors Unmet Needs, KOL's views, Analyst's views, Neuroendocrine Tumors Market Access and Reimbursement

To know what's more in our Neuroendocrine Tumors report, visit https://www.delveinsight.com/report-store/neuroendocrine-tumors-net-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Neuroendocrine Tumors Market Report:
Neuroendocrine Tumors market report covers a descriptive overview and comprehensive insight of the Neuroendocrine Tumors Epidemiology and Neuroendocrine Tumors market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Neuroendocrine Tumors market report provides insights into the current and emerging therapies.
The Neuroendocrine Tumors market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Neuroendocrine Tumors market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Neuroendocrine Tumors market.

Got queries? Click here to know more about the Neuroendocrine Tumors market Landscape https://www.delveinsight.com/sample-request/neuroendocrine-tumors-net-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Neuroendocrine Tumors Patient Share (%) Overview at a Glance
5. Neuroendocrine Tumors Market Overview at a Glance
6. Neuroendocrine Tumors Disease Background and Overview
7. Neuroendocrine Tumors Epidemiology and Patient Population
8. Country-Specific Patient Population of Neuroendocrine Tumors
9. Neuroendocrine Tumors Current Treatment and Medical Practices
10. Unmet Needs
11. Neuroendocrine Tumors Emerging Therapies
12. Neuroendocrine Tumors Market Outlook
13. Country-Wise Neuroendocrine Tumors Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Neuroendocrine Tumors Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Neuroendocrine Tumors Market Outlook 2034 https://www.delveinsight.com/report-store/neuroendocrine-tumors-net-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Neuroendocrine Tumors Pipeline Insights, DelveInsight

"Neuroendocrine Tumors Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Neuroendocrine Tumors market. A detailed picture of the Neuroendocrine Tumors pipeline landscape is provided, which includes the disease overview and Neuroendocrine Tumors treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.